Date of download: 6/2/2016 From: New Protease Inhibitors for the Treatment of Chronic Hepatitis C: A Cost-Effectiveness Analysis Ann Intern Med. 2012;156(4):279-290.

Slides:



Advertisements
Similar presentations
Liver Disease and Thalassaemia George Constantinou.
Advertisements

Hepatitis web study Hepatitis web study Telaprevir in Treatment Naïve GT-1 ADVANCE (Study 108) Phase 3 Treatment Naïve Jacobson IM, et. al. N Engl J Med.
Hepatitis web study Hepatitis web study Telaprevir in Treatment Naïve GT-1 ILLUMINATE (Study 111) Phase 3 Treatment Naïve Sherman KE, et. al. N Engl J.
ALAN FRANCISCUS EXECUTIVE DIRECTOR, HEPATITIS C SUPPORT PROJECT EDITOR-IN-CHIEF, HCV ADVOCATE WEBSITE JOIN ME ON TWITTER & FACEBOOK – HCVADVOCATE BLOG:
Modelled impact of antiviral therapy on the future burden of HCV disease in Scotland Testing/Treatment/Care Working Group, 11 th Sept 2007.
Date of download: 5/28/2016 From: Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B: A Meta-Analysis.
Date of download: 5/28/2016 From: When to Start Antiretroviral Therapy in Resource-Limited Settings Ann Intern Med. 2009;151(3): doi: /
Date of download: 5/28/2016 From: Benefits and Harms of Computed Tomography Lung Cancer Screening Strategies: A Comparative Modeling Study for the U.S.
Date of download: 5/31/2016 From: Cost-Effectiveness of HIV Screening in Patients Older than 55 Years of Age Ann Intern Med. 2008;148(12): doi: /
Date of download: 5/31/2016 From: Benefits, Harms, and Cost-Effectiveness of Supplemental Ultrasonography Screening for Women With Dense Breasts Ann Intern.
Date of download: 6/1/2016 From: Cost-Effectiveness of Radiofrequency Ablation for Supraventricular Tachycardia Ann Intern Med. 2000;133(11): doi: /
Date of download: 6/1/2016 From: Cost-Effectiveness of Novel Regimens for the Treatment of Hepatitis C Virus Ann Intern Med. 2015;162(6): doi: /M
Date of download: 6/1/2016 From: Effects of Mammography Screening Under Different Screening Schedules: Model Estimates of Potential Benefits and Harms.
Date of download: 6/1/2016 From: Cost-Effectiveness of Alternative Management Strategies for Patients with Solitary Pulmonary Nodules Ann Intern Med. 2003;138(9):
Date of download: 6/1/2016 From: Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons Ann Intern Med. 2016;164(2): doi: /M
Date of download: 6/2/2016 From: Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis.
Date of download: 6/3/2016 From: Mortality Rates in Elderly Patients Who Take Different Angiotensin-Converting Enzyme Inhibitors after Acute Myocardial.
Date of download: 6/3/2016 From: Sex, Age, and Birth Cohort Effects in Colorectal Neoplasms: A Cohort Analysis Ann Intern Med. 2010;152(11): doi: /
Date of download: 6/3/2016 From: Cost-Effectiveness of Treatment of Diabetic Macular Edema Ann Intern Med. 2014;160(1): doi: /M Markov.
Date of download: 6/9/2016 From: Escitalopram for the Prevention of Peginterferon-α2a–Associated Depression in Hepatitis C Virus– Infected Patients Without.
Date of download: 6/9/2016 From: Cost-Effectiveness of Preparticipation Screening for Prevention of Sudden Cardiac Death in Young Athletes Ann Intern Med.
Date of download: 6/21/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Cost-effectiveness Analysis of Herpes Simplex Virus.
Date of download: 6/21/2016 From: The Epidemiology of Prescriptions Abandoned at the Pharmacy Ann Intern Med. 2010;153(10): doi: /
Date of download: 6/21/2016 From: HIV, Age, and the Severity of Hepatitis C Virus–Related Liver Disease: A Cohort Study Ann Intern Med. 2013;158(9):
Date of download: 6/21/2016 From: Aspirin, Statins, or Both Drugs for the Primary Prevention of Coronary Heart Disease Events in Men: A Cost–Utility Analysis.
Date of download: 6/22/2016 From: The Efficacy of Influenza Vaccine in Elderly Persons: A Meta-Analysis and Review of the Literature Ann Intern Med. 1995;123(7):
Date of download: 6/22/2016 From: Biomarkers of Inflammation and Thrombosis as Predictors of Near-Term Mortality in Patients with Peripheral Arterial Disease:
Date of download: 6/24/2016 From: Effectiveness of Manual Physical Therapy and Exercise in Osteoarthritis of the Knee: A Randomized, Controlled Trial Ann.
Date of download: 6/25/2016 From: Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic.
Date of download: 6/25/2016 From: Cost-Effectiveness of the Children's Oncology Group Long-Term Follow-up Screening Guidelines for Childhood Cancer Survivors.
Date of download: 6/26/2016 From: Cost-Effectiveness of Adding Cardiac Resynchronization Therapy to an Implantable Cardioverter- Defibrillator Among Patients.
Date of download: 6/26/2016 From: Cost-Effectiveness of Human Papillomavirus Vaccination and Cervical Cancer Screening in Women Older Than 30 Years in.
Date of download: 6/27/2016 From: Population Strategies to Decrease Sodium Intake and the Burden of Cardiovascular Disease: A Cost- Effectiveness Analysis.
Date of download: 6/27/2016 From: Should Colorectal Cancer Screening Be Considered in Elderly Persons Without Previous Screening?: A Cost-Effectiveness.
Date of download: 7/1/2016 From: Evaluating Test Strategies for Colorectal Cancer Screening: A Decision Analysis for the U.S. Preventive Services Task.
Date of download: 7/5/2016 From: Sunscreen and Prevention of Skin Aging: A Randomized Trial Ann Intern Med. 2013;158(11): doi: /
R2. 임형석 / Pf. 김병호. I NTRODUCTION Chronic hepatitis C infection 130~150 million worldwide 7 genotypes genotype 1 predominates(about 70% in USA): most difficult.
Date of download: 7/10/2016 From: Potential Cost-Effectiveness of Prophylactic Use of the Implantable Cardioverter Defibrillator or Amiodarone after Myocardial.
Date of download: 7/10/2016 From: Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label,
Date of download: 7/11/2016 From: Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease Ann Intern Med. 2013;159(6):
Date of download: 9/16/2016 From: Fluorouracil plus Levamisole as Effective Adjuvant Therapy after Resection of Stage III Colon Carcinoma: A Final Report.
Date of download: 9/17/2016 From: Behavioral Therapy to Enable Women with Urge Incontinence to Discontinue Drug Treatment: A Randomized Trial Ann Intern.
Date of download: 9/17/2016 From: The Changing Burden of Hepatitis C Virus Infection in the United States: Model-Based Predictions Ann Intern Med. 2014;161(3):
Date of download: 9/17/2016 From: Topical Treatment of Pressure Ulcers with Nerve Growth Factor: A Randomized Clinical Trial Ann Intern Med. 2003;139(8):
Date of download: 9/18/2016 From: Cost-Effectiveness of Distributing Naloxone to Heroin Users for Lay Overdose Reversal Ann Intern Med. 2013;158(1):1-9.
Date of download: 9/19/2016 From: The Implications of Regional Variations in Medicare Spending. Part 2: Health Outcomes and Satisfaction with Care Ann.
Date of download: 9/19/2016 From: Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C Ann Intern Med. 2000;132(4): doi: /
Date of download: 9/20/2016 From: Massage Therapy versus Simple Touch to Improve Pain and Mood in Patients with Advanced Cancer: A Randomized Trial Ann.
Volume 16, Issue 6, Pages (September 2013)
From: Benefits and Harms of Statin Therapy for Persons With Chronic Kidney DiseaseA Systematic Review and Meta-analysis Ann Intern Med. 2012;157(4):
Classification of virologic responses based on outcomes during and after a 48-week course of pegylated interferon (PEG IFN) plus ribavirin antiviral therapy.
From: Cost-Effectiveness of Genotype-Guided and Dual Antiplatelet Therapies in Acute Coronary Syndrome Ann Intern Med. 2014;160(4): doi: /M
From: Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic AgentsA Cost-Effectiveness.
Ann Intern Med. 1999;130(6): doi: / Figure Legend:
From: Systematic Review: Strategies for Using Exercise Therapy To Improve Outcomes in Chronic Low Back Pain Ann Intern Med. 2005;142(9): doi: /
From: Economic Savings Versus Health Losses: The Cost-Effectiveness of Generic Antiretroviral Therapy in the United States Ann Intern Med. 2013;158(2):84-92.
Markov model structure
From: Treatment of Refractory Whipple Disease with Interferon-γ
From: Low-Molecular-Weight Heparins Compared with Unfractionated Heparin for Treatment of Acute Deep Venous Thrombosis: A Cost-Effectiveness Analysis Ann.
Ann Intern Med. 2009;151(9): doi: / Figure Legend:
From: Low-Molecular-Weight Heparins Compared with Unfractionated Heparin for Treatment of Acute Deep Venous Thrombosis: A Cost-Effectiveness Analysis Ann.
Chronic Hepatitis C Therapy: Changing the Rules of Duration
HCV Protease Inhibitors in Clinical Practice
Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals Liver Cancer - DOI: / Fig. 1. Flowchart of included.
Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non- Cirrhotic Patients: A Societal Perspective  Gihan Hamdy Elsisi, MSc, PhD,
Volume 144, Issue 1, Pages e6 (January 2013)
PI-Based HCV-1 Therapy: Reasons to Hold Off
HCV Protease Inhibitors in Clinical Practice
Chronic Hepatitis C Therapy: Changing the Rules of Duration
Volume 138, Issue 2, Pages e6 (February 2010)
Presentation transcript:

Date of download: 6/2/2016 From: New Protease Inhibitors for the Treatment of Chronic Hepatitis C: A Cost-Effectiveness Analysis Ann Intern Med. 2012;156(4): doi: / Figure 1. Model schematics. The small square represents the decision to implement a policy of standard therapy, universal triple therapy, or IL-28B–guided triple therapy. The small circle with inset “M” indicates the Markov model. During each 12-wk cycle of the model, all persons face a risk for death, depending on their age, sex, race, and health state. Persons begin the model receiving treatment, and if treatment is successful (the patient achieves sustained virologic response), the patient may transition along one of the dashed arrows to a fibrosis stage—stratified, recovered state. Treatment effectiveness is determined by type of treatment, race, fibrosis stage, and IL-28B genotype. If treatment is not successful, the person continues progressing through the natural history of HCV (solid arrows). Death can occur from any health state in the Markov model. HCC = hepatocellular carcinoma; HCV = hepatitis C virus; IL-28B = interleukin-28B; PEG-IFN = pegylated interferon; PI = protease inhibitor; Rb = ribavirin. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

Date of download: 6/2/2016 From: New Protease Inhibitors for the Treatment of Chronic Hepatitis C: A Cost-Effectiveness Analysis Ann Intern Med. 2012;156(4): doi: / Appendix Figure 1. Schematic of first-line response-guided therapy for standard 2-drug therapy. Sustained virologic response is the goal of treatment, and it is measured 24 wk after treatment is stopped. Early virologic response is defined as a reduction of ≥2 log 10 /mL or complete absence of serum HCV RNA at week 12 of treatment compared with the baseline level. EVR = early virologic response; HCV = hepatitis C virus; PEG-IFN = pegylated interferon; Rb = ribavirin; SVR = sustained virologic response. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

Date of download: 6/2/2016 From: New Protease Inhibitors for the Treatment of Chronic Hepatitis C: A Cost-Effectiveness Analysis Ann Intern Med. 2012;156(4): doi: / Appendix Figure 2. Schematic of first-line response-guided therapy for triple therapy strategies. EVR = early virologic response; HCV = hepatitis C virus; PEG-IFN = pegylated interferon; PI = protease inhibitor; Rb = ribavirin; SVR = sustained virologic response. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

Date of download: 6/2/2016 From: New Protease Inhibitors for the Treatment of Chronic Hepatitis C: A Cost-Effectiveness Analysis Ann Intern Med. 2012;156(4): doi: / Figure 2. Cost-effectiveness results: incremental costs incurred and QALYs for each intervention. The graph plots the incremental discounted QALYs (y-axis) and incremental discounted total expected lifetime costs (x-axis) for each treatment strategy separately for cohorts of patients with mild and advanced fibrosis. The solid lines represent the cost-effectiveness frontier, those strategies that are potentially cost-effective depending on one's willingness to pay per unit of health benefit gained, expressed as an incremental cost- effectiveness ratio (defined as the ratio of the additional costs of an intervention and its additional effects compared with the next-best alternative). IL-28B = interleukin-28B; QALY = quality-adjusted life-year. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

Date of download: 6/2/2016 From: New Protease Inhibitors for the Treatment of Chronic Hepatitis C: A Cost-Effectiveness Analysis Ann Intern Med. 2012;156(4): doi: / Appendix Figure 3. Cost-effectiveness results, depending on the fibrosis stage of the cohort. The ICER of strategies on the efficient frontier compared with the next best strategy on the frontier, assuming protease inhibitor costs $1100 per week. ICER = incremental cost-effectiveness ratio; IL-28B = interleukin- 28B; QALY = quality-adjusted life-year. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

Date of download: 6/2/2016 From: New Protease Inhibitors for the Treatment of Chronic Hepatitis C: A Cost-Effectiveness Analysis Ann Intern Med. 2012;156(4): doi: / Appendix Figure 4. Protease inhibitor scenario analysis: ICERs between universal triple therapy using telaprevir to universal triple therapy using boceprevir (base case). ADVANCE = A New Direction in HCV Care: A Study of Treatment-Naive Hepatitis C Patients with Telaprevir; ICER = incremental cost-effectiveness ratio; QALY = quality-adjusted life-year. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

Date of download: 6/2/2016 From: New Protease Inhibitors for the Treatment of Chronic Hepatitis C: A Cost-Effectiveness Analysis Ann Intern Med. 2012;156(4): doi: / Appendix Figure 5. Cost-effectiveness acceptability curve, assuming protease inhibitor costs $1100 per week. The figure shows the probability of each strategy providing the maximum net monetary benefits at various willingness-to-pay thresholds. IL-28B = interleukin-28B; QALY = quality-adjusted life-year. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

Date of download: 6/2/2016 From: New Protease Inhibitors for the Treatment of Chronic Hepatitis C: A Cost-Effectiveness Analysis Ann Intern Med. 2012;156(4): doi: / Appendix Figure 6. Model schematics: 5 strategies. The small square represents the decision to implement a policy of therapy. The small circle with inset “M” indicates the Markov model. IL-28B = interleukin-28B; PEG-IFN = pegylated interferon; PI = protease inhibitor; Rb = ribavirin. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

Date of download: 6/2/2016 From: New Protease Inhibitors for the Treatment of Chronic Hepatitis C: A Cost-Effectiveness Analysis Ann Intern Med. 2012;156(4): doi: / Appendix Figure 7. Overall probability of SVR; by race: 100 treatment effectiveness profiles. SVR = sustained virologic response. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.